Platform

KCI Biotech and its wholly-owned subsidiaries, KMQ Biotech and KAL Biotech, operate as a specialized veterinary CRO providing comprehensive Preclinical veterinary research services for global enterprises and research institutions. Supporting diverse preclinical drug efficacy studies, the platform is equipped with:

Facilities & Animal Resources: 17,600 m² of AAALAC-accredited laboratory animal facilities in Suzhou and Nantong, alongside a 22,400 m² Beagle breeding center.

Disease Model Portfolio: Over 100 types of established animal disease models for canine and feline research.

Infectious Disease Platform: BSL-2 and ABSL-2 accredited experimental facilities designated for the development of anti-infective veterinary drugs and vaccines.

Integrated Analytical Capabilities: Complete experimental services, including veterinary pathology services, toxicology, pharmacokinetics, cell and molecular biology, and medical imaging studies.